Ranitidine bismuth citrate

Generic Medicine Info
Indications and Dosage
Gastric and duodenal ulcers
Adult: 400 mg bid for 4-8 wk.

Benign gastric ulcer
Adult: 400 mg bid for 8 wk.

Eradication of H. pylori associated with peptic ulcer disease
Adult: As triple therapy (ranitidine bismuth citrate 400 mg, clarithromycin 500 mg and amoxicillin 1000 mg): Taken bid for 7 days.
Should be taken with food. Swallow whole, do not chew/crush.
Moderate to severe renal impairment.
Special Precautions
Exclude malignancy prior to therapy. Renal impairment. Elderly, childn. Pregnancy and lactation.
Adverse Reactions
Blackening of tongue and stools; GI upset, headache, mild anaemia, bradycardia, altered liver enzymes. Rarely, hypersensitivity, confusion, hepatitis, pancreatitis, blood dyscrasias, musculoskeletal disorders, male breast symptoms.
Description: Ranitidine bismuth citrate dissociates in the stomach and releases ranitidine and bismuth. It provides a unique combination of properties including inhibition of secretion of gastric acid by competitive antagonism of the action of histamine at the histamine H2-receptor on the gastric parietal cell, mucosal protective effects and anti-H. pylori action.
Chemical Structure

Chemical Structure Image
Ranitidine bismuth citrate

Source: National Center for Biotechnology Information. PubChem Database. Ranitidine bismuth citrate, CID=3033887, https://pubchem.ncbi.nlm.nih.gov/compound/Ranitidine-bismuth-citrate (accessed on Jan. 22, 2020)

MIMS Class
Antacids, Antireflux Agents & Antiulcerants
Buckingham R (ed). Ranitidine Bismuth Citrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/06/2015.

Disclaimer: This information is independently developed by MIMS based on Ranitidine bismuth citrate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in